After talking about the amazing potential of both Spherix Incorporated (NASDAQ:SPEX) and Labopharm Inc. (NASDAQ:DDSS), I was in touch with Spherix Inc. management. They kindly alerted me to one error in my previous article and also to some new information.
In my article I had mentioned that Spherix Inc “Just days ago the company released positive interim results in the phase 3 trial.” This data was actually given to the public back on November 16th, 2009. Here is the link to the press release.
In addition, an email received from Assistant Vice President Matthew Duch let me know that the company will be releasing the full trial results later this year. I continue to expect positive results from Spherix Inc. and believe the stock will move nicely higher in the announcement. I would like to thank Assistant Vice President Matthew Duch for being in touch. I will continue to follow Spherix Inc. and keep you posted on new developments.
Chief Market Strategist
Labopharm Inc. (NASDAQ:DDSS) is the first I wish to highlight. This stock had great news about a week ago when they got FDA approval for their drug OLEPTRO. This drug is an extended release tablet, once-daily formulation of the antidepressant Trazodone. This drug may revolutionize the antidepresent drug market. When the FDA granted Labopharm approval for OLEPTRO, the stock traded close to $3.50 pre market. It opened the day at $2.99 and fell like a rock. This was a classic, sell the news type event. Since then, shorts have piled on board and pushed it to a low two days ago of $1.80. Since then it has rebounded back to just over $2.00. It is very possible to see this stock trade back over $3.00 in the near term on any deals. The key is whether or not they will have to dilute the companies shares to raise capital and how they execute the selling of the drug. I am giving Labopharm a major positive bias at anything under $2.00 with a general trade max to $2.50 - $3.00 short term.
The other company that looks extremely promising is Spherix Incorporated (NASDAQ:SPEX) a small cap biotech with a promising drug on the horizon. Naturlose is the drug used to treat type 2 diabetes. The key revolves around the drug being a natural substance. Just days ago the company released positive interim results in the phase 3 trial. The interim trial showed major reductions in variability of HbA1c levels. As the phase 3 trial winds down, begin to watch this tiny 17 million market cap company inch higher in my opinion. This drug could be a major player in the future. Spherix Inc. will most likely search out a partner and that alone could be the driver of a major move back over $2.00. I am issuing a major positive bias on Spherix Inc. with a possible move over $2.00 in the short term.
Both these companies show themselves to be on the verge of the big time. Whether they get bought out, try and make it on their own or partner up, they have the potential to truly become a monster among small fish.
Chief Market Strategist